“Minneapolis and Boston, May 4th, 2021 – Smiths Medical, a global medical device leader, today announced it has formed an exclusive partnership with Ivenix, Inc. that positions the companies as the first in the U.S. to offer a comprehensive suite of infusion management solutions to meet healthcare needs across the continuum of care. The long-term partnership, which includes a strategic investment from Smiths Medical, unites two innovators under a common goal of revolutionizing infusion management to improve patient safety and meet the needs of healthcare providers today and into the future.
Ivenix, a medical technology company dedicated to eliminating infusion-related patient harm, developed the first and only large-volume infusion pump from the ground up to meet the latest U.S. Food and Drug Administration infusion pump guidelines addressing recurring safety issues with pumps. Ensuring patient safety and clinical efficiency are critical components of successful life-saving infusion management. Today, infusion-related errors account for more than 50% of the 1.5 million adverse drug events reported annually to the FDA, and infusion-related adverse drug events cost the healthcare system more than $2 billion annually.
Smiths Medical’s complementary portfolio of market-leading infusion systems CADD®-Solis and Medfusion® include syringe and ambulatory pumps that serve adult and neonatal critical care, operating rooms and pain management in both the hospital and home. By adding the Ivenix Infusion System to its U.S. product portfolio, Smiths Medical will accelerate its offering into the large-volume infusion device segment, which is estimated to be over $2 billion.”